These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 25040042)

  • 1. The outcome of care in people with type 1 diabetes after switching to insulin glargine-based regimens in a real-life setting: a long-term observational study.
    Dąbrowski M
    Int J Clin Pract; 2014 Aug; 68(8):1020-8. PubMed ID: 25040042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life.
    Pujante Alarcón P; Rodríguez Escobedo R; García Urruzola F; Ares J; Manjón L; Sanchez Ragnarson C; Cacho L; Delgado E; Menéndez Torre EL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):210-216. PubMed ID: 30559088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).
    Pang T; Bain SC; Black RNA; Boyle JG; Elliott J; Holcombe A; Lee KCS; Mulligan C; Saunders L; Yousseif A; Baxter M
    Diabet Med; 2019 Jan; 36(1):110-119. PubMed ID: 30362181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
    Blair HA; Keating GM
    Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
    Garg SK; Gottlieb PA; Hisatomi ME; D'Souza A; Walker AJ; Izuora KE; Chase HP
    Diabetes Res Clin Pract; 2004 Oct; 66(1):49-56. PubMed ID: 15364161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
    Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
    Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
    Porksen NK; Linnebjerg H; Lam ECQ; Garhyan P; Pachori A; Pratley RE; Smith SR
    Diabetes Obes Metab; 2018 May; 20(5):1193-1201. PubMed ID: 29316143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.
    Vargas-Uricoechea H
    J Diabetes Res; 2018; 2018():2052101. PubMed ID: 29619381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin Glargine Dose and Weight Changes in Underweight, Normal Weight, and Overweight Children Newly Diagnosed with Type 1 Diabetes Mellitus.
    Chalk BS; Crane J; Yenokyan G; Pineda EM; Lee CKK
    Pharmacotherapy; 2019 Jul; 39(7):741-748. PubMed ID: 31102482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
    Lamb YN; Syed YY
    BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
    Rosenstock J; Blevins TC; Bergenstal RM; Morrow LA; Qu Y; Jacober SJ
    J Diabetes; 2016 Jan; 8(1):166-9. PubMed ID: 26278063
    [No Abstract]   [Full Text] [Related]  

  • 19. In brief: Semglee - insulin glargine interchangeable with Lantus.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):159-160. PubMed ID: 34550958
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
    Brown MA; Davis CS; Fleming LW; Fleming JW
    J Am Assoc Nurse Pract; 2016 Sep; 28(9):503-9. PubMed ID: 26990724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.